Target Price | $762.52 |
Price | $564.63 |
Potential | 35.05% |
Number of Estimates | 30 |
30 Analysts have issued a price target Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals target price is $762.52. This is 35.05% higher than the current stock price. The highest price target is $1,063.65 88.38% , the lowest is $548.43 2.87% . | |
A rating was issued by 34 analysts: 27 Analysts recommend Regeneron Pharmaceuticals to buy, 6 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2026 of 35.05% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
29 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals sales estimate is $14.1b . This is 0.56% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $15.3b 7.49% , the lowest is $13.1b 7.96% .
This results in the following potential growth metrics:
2024 | $14.2b | 8.27% |
---|---|---|
2025 | $14.1b | 0.48% |
2026 | $14.8b | 4.86% |
2027 | $16.4b | 10.51% |
2028 | $17.4b | 6.48% |
2029 | $18.5b | 6.07% |
2030 | $19.3b | 4.50% |
2031 | $19.7b | 2.16% |
2032 | $19.5b | 1.33% |
15 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2025. The average Regeneron Pharmaceuticals EBITDA estimate is $4.6b . This is 0.12% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.3b 37.21% , the lowest is $3.1b 31.57% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 1.17% |
---|---|---|
2025 | $4.6b | 2.68% |
2026 | $5.3b | 14.80% |
2027 | $6.0b | 14.78% |
2028 | $6.6b | 9.34% |
2029 | $7.1b | 7.54% |
2030 | $7.4b | 4.67% |
2031 | $7.7b | 3.68% |
2032 | $6.8b | 11.01% |
2024 | 33.10% | 8.72% |
---|---|---|
2025 | 32.37% | 2.21% |
2026 | 35.44% | 9.48% |
2027 | 36.81% | 3.87% |
2028 | 37.79% | 2.66% |
2029 | 38.32% | 1.40% |
2030 | 38.38% | 0.16% |
2031 | 38.95% | 1.49% |
2032 | 35.13% | 9.81% |
30 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Regeneron Pharmaceuticals net profit estimate is $4.2b . This is 5.01% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.7b 6.24% , the lowest is $3.6b 19.74% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.4b | 11.61% |
---|---|---|
2025 | $4.2b | 4.02% |
2026 | $4.5b | 5.53% |
2027 | $5.4b | 19.83% |
2028 | $5.8b | 8.77% |
2029 | $6.4b | 9.46% |
2030 | $6.9b | 7.92% |
2031 | $7.3b | 5.66% |
2032 | $7.2b | 1.62% |
2024 | 31.07% | 3.08% |
---|---|---|
2025 | 29.97% | 3.54% |
2026 | 30.16% | 0.63% |
2027 | 32.70% | 8.42% |
2028 | 33.40% | 2.14% |
2029 | 34.47% | 3.20% |
2030 | 35.60% | 3.28% |
2031 | 36.82% | 3.43% |
2032 | 36.71% | 0.30% |
30 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is $39.81 . This is 3.02% lower than earnings per share in the financial year 2024. The highest EPS forecast is $44.52 8.45% , the lowest is $33.63 18.08% .
This results in the following potential growth metrics and future valuations:
2024 | $38.34 | 10.27% |
---|---|---|
2025 | $39.81 | 3.83% |
2026 | $42.01 | 5.53% |
2027 | $50.34 | 19.83% |
2028 | $54.75 | 8.76% |
2029 | $59.93 | 9.46% |
2030 | $64.67 | 7.91% |
2031 | $68.34 | 5.67% |
2032 | $67.23 | 1.62% |
Current | 13.75 | 45.61% |
---|---|---|
2025 | 14.18 | 3.09% |
2026 | 13.44 | 5.22% |
2027 | 11.22 | 16.52% |
2028 | 10.31 | 8.11% |
2029 | 9.42 | 8.63% |
2030 | 8.73 | 7.32% |
2031 | 8.26 | 5.38% |
2032 | 8.40 | 1.69% |
Based on analysts' sales estimates for 2025, the Regeneron Pharmaceuticals stock is valued at an EV/Sales of 3.90 and an P/S ratio of 4.23 .
This results in the following potential growth metrics and future valuations:
Current | 3.87 | 48.74% |
---|---|---|
2025 | 3.90 | 0.70% |
2026 | 3.72 | 4.63% |
2027 | 3.36 | 9.51% |
2028 | 3.16 | 6.08% |
2029 | 2.98 | 5.72% |
2030 | 2.85 | 4.31% |
2031 | 2.79 | 2.12% |
2032 | 2.83 | 1.35% |
Current | 4.21 | 47.78% |
---|---|---|
2025 | 4.23 | 0.57% |
2026 | 4.04 | 4.63% |
2027 | 3.65 | 9.51% |
2028 | 3.43 | 6.08% |
2029 | 3.24 | 5.73% |
2030 | 3.10 | 4.31% |
2031 | 3.03 | 2.12% |
2032 | 3.07 | 1.35% |
Regeneron Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
Jefferies |
Buy
➜
Buy
|
Unchanged | Aug 27 2025 |
Bernstein |
Outperform
➜
Outperform
|
Unchanged | Aug 27 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Aug 11 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Aug 04 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Aug 04 2025 |
Guggenheim |
Buy
➜
Buy
|
Unchanged | Aug 04 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Aug 04 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Jefferies:
Buy
➜
Buy
|
Aug 27 2025 |
Unchanged
Bernstein:
Outperform
➜
Outperform
|
Aug 27 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Aug 11 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Aug 04 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Aug 04 2025 |
Unchanged
Guggenheim:
Buy
➜
Buy
|
Aug 04 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Aug 04 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.